Business Context and Reporting Period
This Form 8-K Current Report was filed by Rexahn Pharmaceuticals, Inc. on February 2, 2015. The report discloses a material corporate event under Regulation FD regarding executive leadership changes.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a personnel appointment and contains no financial statement data.
Material Changes
- Executive Appointment: On February 2, 2015, the Company appointed Ely Benaim, M.D., as Chief Medical Officer.
- Role Responsibilities: Dr. Benaim is responsible for leading clinical development programs and providing strategic and clinical guidance.
- Public Disclosure: A press release announcing this appointment was issued on February 4, 2015.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, outlook statements, risk factors, or contingencies. The document serves solely to disclose the appointment of the new Chief Medical Officer.
Investor Verification Checklist
- Verify the background and qualifications of Ely Benaim, M.D., as the new Chief Medical Officer.
- Review the press release dated February 4, 2015 (Exhibit 99.1) for additional details on the appointment.
- Confirm the impact of this leadership change on the Company's clinical development pipeline in subsequent filings.